Microencapsulation of doxycycline into poly(lactide‐co‐glycolide) by spray drying technique: Effect of polymer molecular weight on process parameters

Abstract

Poly(lactide-co-glycolide) (PLGA) polymers with three different molecular weights were prepared, and microparticles were produced by spray drying and waterin-oil-water (w/o/w) double emulsion techniques to encapsulate 86% of doxycycline (DXY), an antibiotic drug, for the use of periodontitis. Placebo and drug-loaded microspheres and pristine DXY were analyzed by Fourier transform infrared spectroscopy, which indicated no chemical interactions between DXY and PLGA. X-ray diffraction of drug-loaded microspheres confirmed the molecular level dispersion of DXY in PLGA. Scanning electron microscopy confirmed spherical nature and smooth surfaces of the microspheres. Mean particle size as measured by laser light scattering technique ranged between 10 and 25 lm. In vitro release of DXY performed in 7.4 pH media continued up to 72 h and depended on molecular weight of PLGA and extent of DXY loading. Antimicrobial studies performed on one formulation and placebo microspheres suggested that drug concentrations during in vitro release are above the minimum inhibitory concentration (MIC) for Staphylococcus aureus growth. Overall, the release studies depended on the molecular weight of PLGA, extent of drug loading, and the method used to prepare microspheres. Statistical analyses of release data performed using the analysis of variance (ANOVA) method agreed well with experimental observations.

Poly(Lactic-Co-Glycolic Acid) Based Drug Delivery Devices For Tissue Engineering And Regenerative Medicine

“…Blending or co-polymerizing PLGA with other materials, or encapsulating PLGA microparticles in gels, further extends the possibility of controlling drug release (54) . Numerous active pharmaceutical ingredients have been encapsulated in PLGA-based drug delivery systems (DDSs) with proven therapeutic effect in vivo, or have been released in concentrations considered sufficient for therapeutic effect, for example, siRNA (55) , proteins (32) , anti-cancer drugs (53) , analgesic (84) , antibiotics (59) , and vaccines (19) . Among the different forms of PLGA-based DDSs, microspheres or microparticles are the most common.…”

Microencapsulation of Ferrous Fumarate for the Production of Salt Double Fortified with Iron and Iodine

“…It is clear that size, shape, and thus active ingredient protection can be controlled through the selection of materials. For example the molecular weight of encapsulant has been shown to affect particle size (Sun et al, 2009) and shape (Patel et al 2008).…”

Advances in biomimetic regeneration of elastic matrix structures

“…MMP-inhibitors including DOX and minocycline among others have, to the authors’ knowledge, been delivered using micro- and nanocarriers and not scaffold based approaches. DOX has been encapsulated in PLGA [202, 203], PLGA-encapsulated hydroxyapatite microspheres [204], and PLGA-PCL microspheres [205] for controlled release in vitro and in vivo [205]. DOX has also been encapsulated in liposomes [206].…”